enzastaurin has been researched along with Kahler Disease in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benhadji, KA; Hossain, AM; Jourdan, E; Leblond, V; Maisonneuve, H; Moreau, P; Nguyen, TS; Wooldridge, JE | 1 |
| Chang, H; Chen, GA; Chen, J; Chen, Y; Evans, K; Qiu, L; Reece, D; Saha, MN; Yang, Y | 1 |
| Bertacchini, J; Civallero, M; Cosenza, M; Deliliers, GL; Intini, D; Lombardi, L; Neri, A; Nobili, L; Sacchi, S; Todoerti, K; Verdelli, D | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Fruehauf, JH; Hayden, PJ; Hideshima, T; Lin, BK; Munshi, NC; Nguyen, T; Podar, K; Raab, MS; Tonon, G; Zhang, J | 1 |
| Abonour, R; Anderson, KC; Desaiah, D; Ghobrial, IM; Harris, BN; Laubach, JP; Munshi, NC; Myrand, SP; Porter, NM; Richardson, PG; Schlossman, RL; Shi, P; Wooldridge, JE | 1 |
| Anderson, KC; Podar, K | 1 |
| Davies, KM; Ghias, K; Krett, NL; Ma, C; Munshi, HG; Rizvi, MA; Rosen, ST; Weinberg, F | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Lin, BK; McMillin, D; Munshi, N; Podar, K; Raab, MS; Tai, YT; Zhang, J | 1 |
| Armann, J; Baumann, P; Grün, G; Mandl-Weber, S; Oduncu, F; Schmidmaier, R | 1 |
| Bertacchini, J; Civallero, M; Cosenza, M; De Pol, A; Deliliers, GL; Federico, M; Lombardi, L; Marmiroli, S; Neri, A; Nobili, L; Sacchi, S; Tassone, P; Verdelli, D | 1 |
1 review(s) available for enzastaurin and Kahler Disease
| Article | Year |
|---|---|
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
2 trial(s) available for enzastaurin and Kahler Disease
| Article | Year |
|---|---|
A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Protein Kinase Inhibitors; Retreatment; Treatment Outcome | 2014 |
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors | 2011 |
7 other study(ies) available for enzastaurin and Kahler Disease
| Article | Year |
|---|---|
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Multiple Myeloma; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Transplantation; Phosphorylation; Primary Cell Culture; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Survival Analysis | 2015 |
Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
Topics: Cell Cycle; Cell Division; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Indoles; Interferon Regulatory Factors; Multiple Myeloma; Protein Kinase C; Protein Kinase C beta | 2009 |
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.
Topics: Apoptosis; beta Catenin; Cell Division; Cell Line, Tumor; DNA-Binding Proteins; Endoplasmic Reticulum; Gene Expression Regulation, Neoplastic; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Multiple Myeloma; Nuclear Proteins; Protein Kinase C; RNA, Small Interfering; Signal Transduction; Stress, Physiological; Tumor Protein p73; Tumor Suppressor Proteins | 2009 |
Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction | 2006 |
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
Topics: Administration, Oral; Animals; Cell Communication; Coculture Techniques; Cytokines; Drug Delivery Systems; Enzyme Activation; Humans; Indoles; Mice; Multiple Myeloma; Neovascularization, Pathologic; Phorbol Esters; Phosphorylation; Protein Isoforms; Protein Kinase C; Stromal Cells; Transplantation, Heterologous; Tumor Burden; Tumor Cells, Cultured | 2007 |
Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Carbazoles; Cell Proliferation; Cells, Cultured; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Melphalan; Multiple Myeloma; Mutagens; Protein Kinase C; Protein Kinase Inhibitors | 2008 |
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Inhibitory Concentration 50; Multiple Myeloma; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Stromal Cells | 2008 |